# Katalyze AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/katalyze-ai

- Industry: Materials
- Headquarters: Mountain View, US
- Website: www.katalyzeai.com
- Total disclosed funding: $11M
- Latest round: Seed (Jul 6, 2026)
- Investors on record: 4

## About

Katalyze AI, headquartered in Mountain View, US, specializes in providing AI-driven software solutions designed to enhance operational efficiencies within the life sciences sector, particularly for pharmaceutical companies.Founded in 2022 in Mountain View, US, Katalyze AI develops software that integrates various operational systems for the life sciences industry. The company recently completed its first deal in July 2026, raising USD 10.5 mn in Seed funding led by Bonfire Ventures, with participation from Alumni Ventures Group, Inovia Capital, and Ripple Ventures. The total amount raised to date is USD 10.5 mn.Katalyze AI provides an innovative agentic infrastructure tailored specifically for the life sciences industry, designed to streamline operational workflows for pharmaceutical companies. The core product offerings center around an AI-driven platform that integrates various operational systems, allowing data from Manufacturing Execution Systems (MES), Laboratory Information Management Systems (LIMS), Enterprise Resource Planning (ERP), and other sources to form a unified data layer. This integration enables the platform to execute tasks such as batch release management, deviation investigations, and quality control processes with greater efficiency and accuracy. The end users of Katalyze's solutions include large pharmaceutical companies, executives, scientists, and engineers who aim to enhance productivity and reduce operational delays. Key markets for these products include North America, Europe, and Asia, targeting major pharmaceutical hubs where regulatory compliance and operational efficiency are paramount.Katalyze operates on a B2B model, primarily engaging with enterprise clients within the pharmaceutical sector. The company’s revenue structure is based on subscription services for its software platform, where clients pay for access to its agentic infrastructure and AI capabilities. Typical transactions involve annual or multi-year contracts, providing clients with the tools necessary for operational optimization, including streamlining processes like deviation management and enhancing batch release accuracy. The flagship product offers varying service tiers, allowing organizations to choose the level of integration and support that best suits their operational needs. These transactions are structured to build long-term partnerships, ensuring that clients benefit from ongoing updates and enhancements to the platform as technology evolves.In July 2026, Katalyze AI raised USD 10.5 mn in Seed funding to expand its engineering and science teams, develop additional pharmaceutical agents, and increase deployments with pharmaceutical companies. The company plans to launch new products aimed at enhancing its platform's capabilities, although specific release dates have not been announced. Additionally, Katalyze AI aims to expand its market presence in North America, Europe, and Asia, particularly focusing on regions with significant pharmaceutical activity to capitalize on growing demand.

## Funding rounds

- Seed, Jul 6, 2026, $11M — Inovia Capital, Alumni Ventures Group, Bonfire Ventures, Ripple Ventures

## Investors

- Inovia Capital (https://capitalatlas.ai/funds/inovia-capital) — Seed
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Seed
- Bonfire Ventures (https://capitalatlas.ai/funds/bonfire-ventures) — Seed
- Ripple Ventures (https://capitalatlas.ai/funds/ripple-ventures) — Seed